NCT07064707

Rupatadine in Patients With Ulcerative Colitis

Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Mesalamine	Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
DRUG	Rupatadine	Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions

Timeline

• Start date: 2025-07-15
• Primary completion: 2026-07-15
• Completion: 2026-10-21
• First posted: 2025-07-15
• Last updated: 2025-11-19

Locations

1 site across 1 country: Egypt